Neurobiology of disease · 2025
CSF pTDP-43 across the Alzheimer's spectrum: Links to amyloid, APOE and vasculopathy.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Rafiee Zeinab, Pocevičiūtė Dovile, Santiago Jessica, Mahmoud Raneem, Janelidze Shorena, Hansson Oskar, Wennström Malin
Аннотация
INTRODUCTION: Accumulation of phosphorylated TDP-43 (pTDP-43) has been linked to cognitive decline and medial temporal lobe atrophy in Alzheimer's disease (AD), as well as to vascular pathology in individuals with TDP-43 proteinopathy. Our previous findings demonstrated that small perivascular pTDP-43 inclusions are associated with reduced expression of molecules critical for maintaining vascular integrity and function. To further explore the interplay between pTDP-43, amyloid beta (Aβ), and cerebrovascular pathology, we analyzed pTDP-43 levels in cerebrospinal fluid (CSF) samples from patients diagnosed with mild cognitive impairment (MCI), AD, and vascular dementia (VaD).
METHODS: The study included non-demented controls (NC, n = 47), patients with stable MCI (sMCI, n = 55), MCI-AD (patients who later developed AD, n = 32), AD (n = 64), and VaD (n = 30) from a cohort in which markers of Aβ pathology, vasculopathy, and APOE genotypes had previously been determined. Levels of CSF pTDP-43 were measured using an in-house ELISA. Correlations were analyzed between CSF pTDP-43 and biomarkers of Aβ pathology (Aβ40, Aβ42, Aβ40/Aβ42), vascular integrity (sICAM-1, sVCAM-1, VEGF, sFLt-1), and blood-brain barrier permeability (Q-albumin). Additionally, levels of pTDP-43 in postmortem CSF and pTDP-43 load in the hippocampus from cases with AD neuropathological changes (n = 7) were analyzed using the in-house ELISA and immunofluorescent stainings, respectively.
RESULTS: CSF pTDP-43 levels did not differ between diagnostic groups or APOE genotypes. CSF pTDP-43 correlated with Aβ markers in sMCI and VaD. Among the vascular integrity markers, only sFLt-1 correlated with pTDP-43 in VaD. CSF pTDP-43 levels trended to correlate negatively with hippocampal pTDP-43 load.
CONCLUSION: CSF pTDP-43 measured by ELISA cannot distinguish between MCI, AD, and VaD. However, it may reflect hippocampal pTDP-43 burden and is associated with some vascular and Aβ-related changes.
METHODS: The study included non-demented controls (NC, n = 47), patients with stable MCI (sMCI, n = 55), MCI-AD (patients who later developed AD, n = 32), AD (n = 64), and VaD (n = 30) from a cohort in which markers of Aβ pathology, vasculopathy, and APOE genotypes had previously been determined. Levels of CSF pTDP-43 were measured using an in-house ELISA. Correlations were analyzed between CSF pTDP-43 and biomarkers of Aβ pathology (Aβ40, Aβ42, Aβ40/Aβ42), vascular integrity (sICAM-1, sVCAM-1, VEGF, sFLt-1), and blood-brain barrier permeability (Q-albumin). Additionally, levels of pTDP-43 in postmortem CSF and pTDP-43 load in the hippocampus from cases with AD neuropathological changes (n = 7) were analyzed using the in-house ELISA and immunofluorescent stainings, respectively.
RESULTS: CSF pTDP-43 levels did not differ between diagnostic groups or APOE genotypes. CSF pTDP-43 correlated with Aβ markers in sMCI and VaD. Among the vascular integrity markers, only sFLt-1 correlated with pTDP-43 in VaD. CSF pTDP-43 levels trended to correlate negatively with hippocampal pTDP-43 load.
CONCLUSION: CSF pTDP-43 measured by ELISA cannot distinguish between MCI, AD, and VaD. However, it may reflect hippocampal pTDP-43 burden and is associated with some vascular and Aβ-related changes.